Join us at the 11th Global
Pharmaceutical Quality Summit 2026
Join us at the 11th Global
Pharmaceutical Quality Summit 2026
Experience Leucine AI .
‍
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Audit Management
Audit Management
View Detailed Analysis

Analytics Overview

40
Form 483s Issued
5
483s converted to WL
40
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
05 Aug 2026
ModernaTX, Inc.
Drugs
10 Mar 2026
Hospira, Inc.
Drugs
26 Feb 2026
Bear-Ent, Llc
Drugs
20 Feb 2026
Seniorlife Technologies Inc
Drugs
10 Feb 2026
PACKAGE SOLUTIONS LLC
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Hyesuk Kong
3
0
Justin A Boyd
3
1
Carl Perez
3
0
Donald Ertel
3
0
Kevin Matthews
3
0
TITLE/ COMPANY Issue Date Status Details
A Form FDA 483 Inspectional Observations was issued at the conclusion of the inspection.
ModernaTX, Inc.
05 Aug 2026 Normal Justification: The process of receiving, responding, and resolving FDA 483 observations inherently involves audit management skills.
Excerpt: The firm responded to the observations, and the corrective actions were reviewed and found to be adequate.
View Details
Pre-License Inspection #1
Vascular Solutions, LLC
29 Jun 2026 Normal Justification: Pre-License Inspection #1 implies serious gaps in audit management, considering the volume of observations.
Excerpt: Form FDA 483 issued with 14 observations
View Details
Your firm lacks adequate quality oversight to ensure Acceptable Quality Level (AQL) samples are taken
Hospira, Inc.
10 Mar 2026 Normal Justification: As per SOP-96072, auditing is a control point for sampling adherence but failed, necessitating process audit improvement.
Excerpt: Auditing of Production Operations, Section E.3 clarifies representation requirement, suggesting auditing lapses contributed.
View Details
Internal audits have not been conducted at planned intervals
Bear-Ent, Llc
26 Feb 2026 Normal Justification: Audit Management process crucial as the audit schedule's absence directly links to lapses in systematic risk assessments.
Excerpt: No internal audits or audit schedules have been completed for 2023, 2024, and 2025.
View Details
Internal audits have not been adequately conducted at planned intervals to determine whether the QMS
Seniorlife Technologies Inc
20 Feb 2026 Normal Justification: Audit Management is implicated due to non-compliance with documented audit procedures and incomplete audit coverage.
Excerpt: Your firm does not adhere to the requirement that each organization shall document procedures for quality audits.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Audit Management

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Audit Management

Overview

40
Form 483s Issued
5
483s converted to WL
40
Total Observation
Form 483s Issued
+74 from last period

Recent Form 483s & Warning Letters

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
05 Aug 2026
ModernaTX, Inc.
Drugs
10 Mar 2026
Hospira, Inc.
Drugs
26 Feb 2026
Bear-Ent, Llc
Drugs
20 Feb 2026
Seniorlife Technologies Inc
Drugs
10 Feb 2026
PACKAGE SOLUTIONS LLC
Drugs

Top FDA Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Hyesuk Kong
3
0
Justin A Boyd
3
1
Carl Perez
3
0
Donald Ertel
3
0
Kevin Matthews
3
0

Key Observations

TITLE/ COMPANY Issue Date Status Details
A Form FDA 483 Inspectional Observations was issued at the conclusion of the inspection.
ModernaTX, Inc.
05 Aug 2026 Normal Justification: The process of receiving, responding, and resolving FDA 483 observations inherently involves audit management skills.
Excerpt: The firm responded to the observations, and the corrective actions were reviewed and found to be adequate.
View Details
Pre-License Inspection #1
Vascular Solutions, LLC
29 Jun 2026 Normal Justification: Pre-License Inspection #1 implies serious gaps in audit management, considering the volume of observations.
Excerpt: Form FDA 483 issued with 14 observations
View Details
Your firm lacks adequate quality oversight to ensure Acceptable Quality Level (AQL) samples are taken
Hospira, Inc.
10 Mar 2026 Normal Justification: As per SOP-96072, auditing is a control point for sampling adherence but failed, necessitating process audit improvement.
Excerpt: Auditing of Production Operations, Section E.3 clarifies representation requirement, suggesting auditing lapses contributed.
View Details
Internal audits have not been conducted at planned intervals
Bear-Ent, Llc
26 Feb 2026 Normal Justification: Audit Management process crucial as the audit schedule's absence directly links to lapses in systematic risk assessments.
Excerpt: No internal audits or audit schedules have been completed for 2023, 2024, and 2025.
View Details
Internal audits have not been adequately conducted at planned intervals to determine whether the QMS
Seniorlife Technologies Inc
20 Feb 2026 Normal Justification: Audit Management is implicated due to non-compliance with documented audit procedures and incomplete audit coverage.
Excerpt: Your firm does not adhere to the requirement that each organization shall document procedures for quality audits.
View Details

Frequently Asked Questions

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources